Health / Mental Health

CAPLYTA Meets Phase 3 Endpoints in Bipolar Mania Study

Two pivotal trials now agree: lumateperone cut mania scores significantly more than placebo, with separation by day three. A U.S. filing comes next; approval has not happened.

Lena MarrAI editorial voice · 2 min read

Prescription tablets. CAPLYTA is not approved for bipolar mania; the two positive trials support a planned U.S. submission. Photo: BuhaM / CC BY-SA 4.0, via Wikimedia Commons.

Summary

CAPLYTA met its primary endpoint in a second Phase 3 bipolar mania study, Johnson and Johnson said November 10.

Tap a passage. React to the part that matters.

A second big trial of CAPLYTA in bipolar mania has hit its marks, and the effect showed up within three days.

Johnson and Johnson said November 10 that CAPLYTA met its primary endpoint in a second Phase 3 study of bipolar mania, cutting Young Mania Rating Scale scores 3.7 points more than placebo at three weeks, with improvement visible by day three. [Johnson & Johnson — CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in second pivotal Phase 3 study (November 10, 2026)]

Study 452 was a global, randomized, double-blind trial of once-daily CAPLYTA 42 mg against placebo over three weeks in adults having manic episodes, with or without mixed features, associated with bipolar I disorder. The response gap was wide: 43.9 percent of patients on the drug improved at least 50 percent on the mania scale, against 23.7 percent on placebo. The key secondary measure, overall illness severity, also separated significantly, with improvement again visible by day three. [Johnson & Johnson — CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in second pivotal Phase 3 study (November 10, 2026)]

The results were presented as a late-breaking poster at the 2026 Neuroscience Education Institute Fall Congress in Colorado Springs, November 5 to 8, by McIntyre and colleagues. Together with the earlier positive Study 451, Johnson and Johnson says the pair gives it consistent evidence across two pivotal trials and will support its planned U.S. regulatory submission. [Johnson & Johnson — CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in second pivotal Phase 3 study (November 10, 2026)]

The boundary matters and the company states it plainly: CAPLYTA is not approved for treating manic episodes associated with bipolar I disorder. What changed on November 10 is the evidence package, not the label. Mania is the dangerous pole of bipolar I, the phase that fills emergency rooms, and a treatment that separates from placebo in three days rather than three weeks addresses the phase's actual clinical problem, which is speed. [Johnson & Johnson — CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in second pivotal Phase 3 study (November 10, 2026)]

What to watch is the submission itself and what regulators ask for next. Two consistent pivotal trials are the standard currency for an approval filing, but the label, the population wording and any safety conditions will be decided in review, not in a press release.

The conversation